Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
SALURON (hydroflumethiazide) is an oral thiazide diuretic tablet approved in 1959 for the treatment of hypertension and edema. It works by inhibiting sodium and chloride reabsorption in the distal convoluted tubule, reducing blood volume and lowering blood pressure. The drug represents a foundational class in cardiovascular therapy with decades of clinical use.
As LOE approaches, the brand team is likely transitioning to life-cycle management and defending against generic competition; headcount may be consolidating.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety And Efficacy Of Spirinolactone Plus Hydroflumethiazide In The Treatment Of Filipino Patients With Hypertension
SALURON offers limited career momentum as a legacy branded product approaching loss of exclusivity with minimal job openings. Roles available are primarily defensive in nature, focused on protecting market share and managing the transition to generic competition rather than driving growth.
Worked on SALURON at Takeda? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.